Suboxone Lawsuit Payout Per Person: 2026 Guide

Quick Answer
– The Suboxone litigation runs on two tracks: a product liability case over drug-induced tooth decay (MDL 3092, N.D. Ohio) and an antitrust case over generic drug suppression (MDL 2445, E.D. Pennsylvania).
– Individual payouts in the product liability track are estimated between $10,000 and $150,000+ depending on injury severity, documentation, and bellwether trial outcomes.
– Qualifying claimants used Suboxone film strips, suffered documented dental injuries, and must act before applicable state statutes of limitations expire, several of which create effective 2026 deadlines.

Case Snapshot

The Suboxone litigation is one of the more significant pharmaceutical mass torts active in the federal court system in 2026. The suboxone lawsuit payout per person depends on which legal track a claimant falls under, the severity of dental damage they can document, and how bellwether trial outcomes ultimately calibrate the settlement grid.

Thousands of patients who used Suboxone sublingual film to treat opioid use disorder now allege the manufacturer knew the product caused severe dental damage and concealed that risk for years. The FDA confirmed the connection in January 2022 with a formal safety communication.

For more context, see Aspen Dental Lawsuit 2026: Claims, Payouts & Class Action

The litigation sits in two separate federal courts simultaneously. That dual-track structure affects how payouts are calculated, who benefits, and when money actually moves.

Understanding both tracks, and the compensation tiers within each, is the starting point for any realistic assessment of individual recovery.

Suboxone Lawsuit Payout Per Person: What the Numbers Actually Look Like

The suboxone lawsuit payout per person is not a fixed figure. Payouts are determined by a combination of injury severity, documentation quality, and how bellwether trial verdicts establish the settlement baseline within MDL 3092.

In comparable pharmaceutical product liability MDLs, individual claimants have received anywhere from several thousand dollars for minor documented injuries to mid-six figures for catastrophic dental losses requiring full mouth reconstruction. Based on the injury profile alleged in MDL 3092, legal analysts tracking the litigation estimate individual payouts ranging from $10,000 to $150,000 or more for the most severe cases.

Those figures are not guarantees. They reflect what the current state of the litigation, prior pharmaceutical MDL outcomes, and the documented injury patterns suggest is a realistic range.

Estimated Payout Range by Injury Category:

*Attorney Insight: Attorneys handling these claims note that documented dental treatment costs are the single most important factor in determining which tier a claimant lands in, making thorough record collection essential from day one.*

How Much Will You Get From the Suboxone Lawsuit?

What any individual receives depends on five specific variables. Generic estimates without accounting for these variables are unreliable.

The five primary variables are:

• Duration of Suboxone film use (longer use correlates with greater documented damage)
• Severity of dental injury (number of teeth affected, procedures required)
• Quality of medical and dental records (documented diagnosis and treatment timeline)
• State of residence (affects statute of limitations and applicable damages rules)
• Bellwether trial outcomes (verdicts set the negotiating floor for all remaining claimants)

In practice, settlement negotiations in MDL cases do not happen in isolation. The Plaintiff Steering Committee negotiates a global framework with the defendant. Individual attorneys then position each client's claim within that framework based on those five variables.

Litigation Watch: The gap between a $10,000 floor and a $150,000+ ceiling reflects real differences in documented injury, not attorney skill, which makes early and thorough records collection the most consequential step any claimant can take.

*Attorney Insight: Attorneys handling these claims consistently report that claimants who gather dental records dating back to the start of their Suboxone film use receive significantly stronger settlement positioning than those who rely on memory alone.*

Suboxone Settlement Amount Per Person: How the Math Works

Settlement math in a pharmaceutical MDL is not arbitrary. It follows a point-based or tier-based valuation system established by the Plaintiff Steering Committee and the defendant's counsel once enough bellwether data exists.

In MDL 3092, the valuation framework has not yet been publicly disclosed because no global settlement has been announced as of 2026. That is consistent with where the litigation sits on the timeline. Bellwether trials are the mechanism that forces the math.

Once one or two bellwether juries return verdicts, both sides have real data on what a jury is willing to award for a specific injury profile. The defendant uses that data to calculate its litigation risk across thousands of cases. That risk calculation becomes the settlement fund.

Prior pharmaceutical MDLs offer useful reference points:

*Attorney Insight: Attorneys tracking MDL 3092 point to the Juul and talcum powder frameworks as the most structurally similar to what Suboxone claimants should expect, where a large global fund is divided through a tiered point system.*

Suboxone Lawsuit Compensation Tiers: What Category Are You In?

Compensation tiers are the architecture of every large pharmaceutical settlement. They sort claimants by injury severity and assign point values that translate into dollar amounts once the total fund is finalized.

In MDL 3092, no official tier structure has been publicly filed as of 2026. However, based on the injury allegations in the master complaint and how comparable dental injury MDLs have structured their grids, the expected tier categories track closely to the injury severity table presented above.

What determines tier placement:

• Number of teeth with documented damage
• Type of dental procedures required (fillings vs. extractions vs. implants)
• Ongoing vs. resolved treatment status
• Duration of Suboxone film use correlated with injury onset timeline
• Whether the patient's dental baseline before Suboxone use is documented

Claimants with pre-existing dental conditions face additional scrutiny. Defendants routinely argue that damage predates product use. Strong dentist records from before and during Suboxone film use directly counter that defense.

*Attorney Insight: Attorneys handling these claims advise claimants to request complete records from every dentist visited in the five years before starting Suboxone film and every year during use, because that chronological record is the strongest counter to a causation defense.*

Suboxone Lawsuit Settlement Fund Total: What Has Been Committed

No global settlement fund for MDL 3092 has been announced as of early 2026. The litigation is in active pre-trial development, with bellwether discovery and scheduling orders guiding the timeline.

Indivior PLC has significant prior settlement history that establishes the company's capacity and legal posture. In 2020, Indivior agreed to a $600 million criminal and civil settlement with the U.S. Department of Justice over separate marketing fraud allegations. That settlement is distinct from the current dental injury and antitrust litigation.

The antitrust track under MDL 2445 has seen more movement. End-payor plaintiffs and direct-payor plaintiffs have pursued separate class certification proceedings in the Eastern District of Pennsylvania.

Key financial reference points:

*Attorney Insight: Attorneys handling these claims note that Indivior's prior $600M DOJ resolution demonstrates the company's willingness to settle large-scale liability rather than face open-ended trial exposure, a dynamic that tends to accelerate MDL settlement negotiations once bellwether verdicts establish a pricing floor.*

Litigation Watch: No global MDL 3092 settlement fund exists yet in 2026, which means claimants who have not filed are still within the window to join the litigation before any settlement agreement closes the intake period.

Who Qualifies for the Suboxone Lawsuit?

Qualifying for the suboxone lawsuit requires meeting a specific set of use and injury criteria. Not all Suboxone users qualify, and not all dental problems connected to any medication automatically create a viable claim.

Core qualifying criteria for MDL 3092:

• Used Suboxone film strips (sublingual or buccal film formulation), not the tablet form
• Used the film for a meaningful duration (most accepted claims involve use of 90 days or more)
• Developed dental injuries after beginning Suboxone film use
• Dental injuries are documented by a treating dentist or oral health provider
• Injuries are not fully explained by pre-existing dental conditions independent of the film

The product at issue is specifically the film formulation. The sublingual tablet version of buprenorphine/naloxone is not part of MDL 3092. This distinction is frequently misunderstood and results in non-qualifying claims being submitted.

Who does not qualify:

• Patients who used only Suboxone tablets, not film strips
• Patients whose dental records show equivalent damage predating Suboxone film use
• Patients with no documented dental treatment related to the alleged injuries

*Attorney Insight: Attorneys handling these claims report that the film-versus-tablet distinction is the first gatekeeping question asked during intake screening, and confirming which formulation a client received is a threshold issue before any other evaluation.*

Suboxone Lawsuit Eligibility Requirements: The Documentation You Need

Eligibility in practice means documentation. A claimant may have a genuine injury and still not have a viable claim without the records to prove it.

Required documentation categories:

• Prescription records confirming Suboxone film use (pharmacy records, prescriber records)
• Dental records showing the condition of teeth before and after Suboxone film use
• Treatment records for all dental procedures attributed to Suboxone-induced damage
• Dental bills and out-of-pocket cost documentation
• Medical records from treating physicians who noted dental side effects

Optional but strengthening documentation:

• Photographs of dental damage
• Statements from treating dentists connecting the injury to sublingual film use
• Records of complaints made to prescribing physicians about dental symptoms

Courts presiding over MDL 3092 will require a Plaintiff Fact Sheet. That document captures the core details of each claimant's product use and injury history. Incomplete or inconsistent Plaintiff Fact Sheets are a primary reason claims are dismissed within MDL proceedings.

*Attorney Insight: Attorneys handling these claims treat the Plaintiff Fact Sheet as the single most important filing in the early stage of an MDL claim, and experienced mass tort firms often spend significant time with each client reviewing every answer before submission.*

This is also helpful: Shein Lawsuit 2026: Claims, Status and Who Qualifies

Suboxone Dental Injury Lawsuit: What the Science Says

The scientific basis for MDL 3092 is grounded in the FDA's January 2022 drug safety communication. That formal agency communication confirmed that buprenorphine-containing medicines dissolved in the mouth, including Suboxone film strips, can cause dental problems including tooth decay, cavities, oral infections, and tooth loss.

The FDA's warning specifically addressed the sublingual and buccal film delivery mechanism. The sustained acidic pH environment created by dissolving the film against oral tissue is the proposed mechanism of damage.

Key scientific and regulatory timeline:

The failure-to-warn theory is central to MDL 3092. Plaintiffs allege Indivior knew or should have known about the dental risk years before the 2022 FDA warning and failed to update prescribers or patients.

*Attorney Insight: Attorneys handling these claims point to internal company communications and adverse event reports submitted to the FDA as key discovery targets, because documents showing pre-2022 awareness of dental side effects would significantly strengthen the failure-to-warn theory.*

Litigation Watch: The FDA's January 2022 dental safety communication functions as a foundational liability document in MDL 3092, establishing agency-level confirmation of the risk that Indivior allegedly failed to adequately disclose.

Suboxone Tooth Decay Lawsuit Settlement: The Product Liability Track

The product liability track is the primary driver of individual claimant compensation in the Suboxone litigation. MDL 3092, formally titled In re: Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation, consolidates individual personal injury claims from across the country.

Centralization in the Northern District of Ohio before Judge David A. Ruiz was ordered to coordinate pretrial proceedings efficiently. Cases filed in federal court nationwide are transferred to N.D. Ohio for discovery, motions practice, and bellwether trial selection.

How the product liability track works:

1. Individual plaintiffs file in federal court or are directly filed into MDL 3092
2. All claims are transferred to N.D. Ohio for coordinated pretrial proceedings
3. A Plaintiff Steering Committee (PSC) manages litigation strategy on behalf of all plaintiffs
4. Bellwether cases are selected to represent the broader plaintiff pool
5. Bellwether trials produce verdicts that establish the settlement baseline
6. A global settlement is negotiated based on those verdicts
7. Individual claimants receive compensation through the settlement fund according to their tier

The product liability track specifically targets Indivior's alleged failure to warn patients and prescribers about dental injury risks associated with the film formulation.

*Attorney Insight: Attorneys handling these claims emphasize that the MDL structure means an individual plaintiff does not have their own separate trial in most circumstances; instead, their compensation is determined by the settlement framework negotiated at the MDL level, making the quality of their documented claim the key to maximizing recovery.*

Indivior Suboxone Lawsuit Settlement: Corporate Accountability and Prior Payouts

Indivior PLC is the primary defendant in both MDL 3092 and MDL 2445. The company was spun off from Reckitt Benckiser Group in 2014 and has faced sustained government and private litigation since.

The most significant prior resolution was the 2020 federal criminal and civil settlement with the U.S. Department of Justice. Indivior and its subsidiary agreed to pay $600 million to resolve allegations of fraudulent marketing of Suboxone film to increase prescriptions. Indivior's subsidiary, Indivior Solutions Inc., entered a criminal guilty plea.

That prior resolution is legally and factually distinct from the current dental injury litigation. However, it is relevant to the current litigation in two specific ways: it establishes Indivior's pattern of conduct regarding Suboxone marketing, and it provides plaintiffs' attorneys with prior government findings about how the company managed disclosures about its product.

Indivior litigation history:

*Attorney Insight: Attorneys handling these claims note that Indivior's prior criminal resolution, while distinct in theory, is admissible context in certain pretrial motions and may influence how aggressively the company defends against the current wave of dental injury claims.*

Suboxone Antitrust Lawsuit Settlement: The Second Legal Track

The antitrust track of the Suboxone litigation is fundamentally different from the dental injury claims and affects a different class of claimants. MDL 2445, In re: Suboxone (Buprenorphine/Naloxone) Film Antitrust Litigation, is centralized in the Eastern District of Pennsylvania before Judge Mitchell S. Goldberg.

The antitrust claims allege that Indivior and Reckitt Benckiser engaged in anticompetitive conduct to delay generic competition for Suboxone film. Tactics alleged include product-hopping from tablets to film to reset patent exclusivity, and filing sham citizen petitions with the FDA to block generic entry.

Who benefits from the antitrust track:

• Health insurers and pharmacy benefit managers who paid inflated prices for Suboxone film
• End-payor patients who paid out-of-pocket co-pays at inflated brand-name prices
• Entities that would have purchased lower-cost generic versions earlier

The antitrust and product liability tracks serve different injured parties. A patient can potentially participate in both if they paid inflated prices AND suffered dental injuries, but the claims are separate and require separate legal representation and analysis.

*Attorney Insight: Attorneys handling antitrust track claims note that the class certification process in MDL 2445 has been the central battleground, and the outcome of class certification rulings directly determines how much money flows to end-payor class members.*

Litigation Watch: Claimants who paid out-of-pocket costs for Suboxone film prescriptions between 2010 and the entry of generic competition may have antitrust claims entirely separate from and in addition to any dental injury claim they hold.

Suboxone MDL 3092 Update 2026: Where the Cases Stand Now

MDL 3092 entered 2026 in the active discovery and bellwether preparation phase. Judge David A. Ruiz in the Northern District of Ohio has presided over coordinated scheduling orders that move the litigation toward trial selection.

As of 2026, the docket reflects several thousand individual plaintiff cases centralized in the MDL. Plaintiff Fact Sheet deadlines have passed for early-wave claimants. The Plaintiff Steering Committee is operating under a case management order that establishes the discovery cutoff and bellwether selection timeline.

MDL 3092 status indicators in 2026:

The trajectory of MDL 3092 follows the standard pharmaceutical MDL arc. The litigation is moving, not stalled. That is significant for claimants considering whether to file.

*Attorney Insight: Attorneys monitoring the MDL 3092 docket report that Judge Ruiz has maintained an active case management posture, with regular status conferences and deadlines that keep the litigation progressing toward the bellwether trial phase that precedes global settlement.*

On a related note, check out Drake UMG Lawsuit 2026: Claims, Court Status, Outcome

Suboxone Lawsuit Filing Deadline 2026: When Time Runs Out

The filing deadline for the Suboxone lawsuit is not a single national date. It is governed by each state's statute of limitations for product liability claims, which varies from one to six years depending on the state.

The FDA's January 2022 dental safety communication is the critical reference point. Most states' statutes of limitations began running for Suboxone dental injury claimants no later than that date, because that is when the risk was publicly confirmed. Some states apply discovery rules that could extend or contract that period.

State-by-state statute of limitations snapshot:

Note: Discovery rule exceptions, minority status, and fraudulent concealment doctrines can alter these dates. A plaintiff who was on active Suboxone film use and developed dental symptoms after January 2022 would have a later start date for their limitations period.

*Attorney Insight: Attorneys handling these claims are aggressive about filing deadline analysis because statutes of limitations in MDL cases are not suspended simply by the existence of the MDL; each individual claim must be timely under applicable state law, and late claims are dismissed with no recovery.*

Suboxone Lawsuit Bellwether Trials: How Trial Verdicts Set Settlement Values

Bellwether trials are the mechanism by which an MDL converts from a pre-settlement holding pattern into a resolved compensation system. In MDL 3092, bellwether trial selection is the pivotal procedural milestone of 2026.

A bellwether trial selects a small number of representative cases from the full plaintiff pool and tries them to verdict. The cases are chosen to represent a cross-section of injury profiles. Verdicts from these trials give both sides real data on how juries value specific injuries in the Suboxone dental damage context.

How bellwether verdicts affect payouts:

• A high plaintiff verdict signals that Indivior's litigation exposure across thousands of similar cases is substantial, creating pressure to settle globally at a figure that reflects that risk.
• A defense verdict signals the opposite, strengthening Indivior's negotiating position and potentially lowering the settlement fund total.
• Most pharmaceutical MDLs settle after the first one or two bellwether verdicts, before a third trial forces another data point.

The bellwether process in MDL 3092 is why claimants who have not yet filed face increasing urgency in 2026. Settlement negotiations typically happen after bellwether verdicts. Once a global settlement is announced, new claimants either cannot join or join at less favorable terms than those already in the MDL.

*Attorney Insight: Attorneys handling these claims explain that the window between bellwether trial scheduling and global settlement announcement is often the last practical opportunity to file with full access to the settlement compensation grid, and that window is typically measured in months, not years.*

Frequently Asked Questions

How much is the average suboxone lawsuit payout per person?

The suboxone lawsuit payout per person is estimated to range from $10,000 to $150,000 or more depending on injury severity and documentation.

No global settlement has been finalized in MDL 3092 as of 2026, so final per-person amounts will be set once bellwether trial outcomes establish the compensation baseline.

What injuries qualify for the suboxone tooth decay lawsuit?

Qualifying injuries include cavities, enamel erosion, tooth loss, abscesses, oral infections, and any dental condition that developed or significantly worsened after beginning Suboxone film strip use.

The condition must be documented by a treating dentist and must not be fully attributable to pre-existing dental disease.

What is the filing deadline for the suboxone lawsuit in 2026?

There is no single national deadline; each state's product liability statute of limitations governs when a claimant's time expires.

Most two-year-SOL states calculated from the FDA's January 2022 dental warning have deadlines that have passed, but discovery rule exceptions and later-onset injuries can extend filing windows, making an attorney consultation essential.

What is MDL 3092 and how does it affect my claim?

MDL 3092 is the federal court proceeding that consolidates all Suboxone film dental injury cases in the Northern District of Ohio before Judge David A. Ruiz.

Being part of MDL 3092 means a claimant's case is handled through coordinated pretrial proceedings, with individual compensation determined through a global settlement framework rather than a separate personal trial.

Do I need dental records to file a suboxone lawsuit claim?

Dental records are not technically required to file, but they are essential to building a viable and well-compensated claim.

Without records documenting the dental injuries and their timing relative to Suboxone film use, a claim faces dismissal or placement in the lowest compensation tier.

Can I still file a suboxone lawsuit claim in 2026?

Many claimants can still file in 2026, particularly those in states with three-year statutes of limitations, those whose dental injuries were diagnosed after January 2023, or those whose limitations periods were tolled.

The fastest way to determine eligibility is to consult a mass tort attorney who handles pharmaceutical product liability claims, because the statute of limitations analysis is fact-specific to each claimant.

Closing

The Suboxone litigation is active, funded by a defendant with prior settlement history, and moving toward the bellwether trial phase that typically precedes a global resolution. For claimants with documented dental injuries from Suboxone film use, the compensation potential is real and tiered by the quality of their records.

The statute of limitations is not a background detail. It is the threshold condition that determines whether a claim exists at all. In 2026, that clock is still running for many potential claimants and has already expired for others.

If the injury timeline and product use described here apply to your situation, the next concrete step is a consultation with an attorney who handles pharmaceutical mass tort cases, specifically one with active involvement in MDL 3092.

Before you go further, consider reading Baby Food Lawsuit 2026: Claims, Eligibility & Settlements